The overall risk of autologous hemotherapy, consisting of the risks due to donation and transfusion, has to be lower than that of homologous hemotherapy. To maintain the advantage of autologous blood, for example preoperative blood deposit, it has to be collected and prepared according to the guidelines on the production of homologous blood, except some obvious deviations concerning donor criteria. In this paper we recommend measures for the quality assurance in autologous predeposits from the point of view of transfusion medicine.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Operative Repair of Type A Aortic Dissection in Jehovah's Witnesses: Insights From a Case Series.
Ann Thorac Surg Short Rep
March 2024
Division of Cardiothoracic Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama.
Background: Jehovah's Witnesses are known to refuse allogeneic blood products. Consequently, many surgeons will decline to perform aortic surgery on this patient group, given their higher risk. We present here a case series describing operative repair of type A aortic dissection without the use of allogeneic blood products.
View Article and Find Full Text PDFEffect of pre-conception serum vitamin D level on pregnancy outcomes in women undergoing in vitro fertilization with fresh embryo transfer: a retrospective analysis.
Reprod Biol Endocrinol
January 2025
Department of Obstetrics and Gynaecology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, 6/F Professorial Block Queen Mary Hospital 102 Pok Fu Lam Road, Hong Kong, China.
Background: This study aims to investigate the association of pre-conception vitamin D levels on adverse pregnancy outcomes in women undergoing in vitro fertilization with fresh embryo transfer.
Methods: This was a retrospective cohort study using archived serum 25-hydroxyvitamin D measured in the pre-conception period before ovarian stimulation in patients undergoing in vitro fertilization with fresh autologous embryo transfer. A total of 306 women were included and adverse pregnancy outcomes in their resulting pregnancy were recorded.
Advancing brain immunotherapy through functional nanomaterials.
Drug Deliv Transl Res
January 2025
Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, 300044, Hsinchu, Taiwan.
Glioblastoma (GBM), a highly aggressive brain tumor, poses significant treatment challenges due to its highly immunosuppressive microenvironment and the brain immune privilege. Immunotherapy activating the immune system and T lymphocyte infiltration holds great promise against GBM. However, the brain's low immunogenicity and the difficulty of crossing the blood-brain barrier (BBB) hinder therapeutic efficacy.
View Article and Find Full Text PDFEfficacy comparison of sodium hyaluronate, corticosteroids, and autologous platelet-rich plasma in the treatment of primary frozen shoulder.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
August 2024
Department of Orthopedics, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Objectives: Primary frozen shoulder is a shoulder joint disease that severely impacts the quality of life of patients, and intra-articular injection is a common treatment method. This study aims to evaluate and compare the therapeutic effects of sodium hyaluronate (SH), corticosteroids (CS), and autologous platelet-rich plasma (PRP) in the treatment primary frozen shoulder.
Methods: A total of 117 patients diagnosed with primary frozen shoulder and treated with a single injection of SH, CS, or PRP into the glenohumeral joint under ultrasound guidance at the Third Xiangya Hospital of Central South University from January 1, 2020, to December 31, 2022, were included in the study.
Should CAR-T cell therapy be considered a standard of care for patients with refractory diffuse large B-cell lymphoma in second line treatment?
Expert Opin Biol Ther
January 2025
Department of Malignant Hematology, Moffitt Cancer Center, Tampa, USA.
Introduction: CAR-T therapy has transformed the treatment landscape for relapsed/refractory diffuse large B-cell lymphomas (DLBCL).
Areas Covered: This article reviews the existing evidence for using CAR-T therapy as a second-line treatment. Two major phase 3 trials, ZUMA-7 and TRANSFORM, have shown that axi-cel and liso-cel, respectively, offer superior outcomes compared to historical standard chemoimmunotherapy and consolidation with autologous hematopoietic stem cell transplantation (auto-HCT).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!